ConductScience.org, home

Paper39436655

eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations.

Valcikova B and 14 others. Proc Natl Acad Sci U S A, 2024. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations. Papers, record 39436655. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39436655

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations.
PubMed
Journal
Proc Natl Acad Sci U S A
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
1.55, provisional
iCite
Revised in PubMed
2026-08-07
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Valcikova BBarborahttps://orcid.org/0000-0002-1830-8084
2Vadovicova NNataliahttps://orcid.org/0000-0002-0691-4714
3Smolkova KKarolina
4Zacpalova MMagdalenahttps://orcid.org/0000-0002-3675-2381
5Krejci PPavelhttps://orcid.org/0000-0003-0618-9134
6Lee SShannon
7Rauch JJens
8Kolch WWalterhttps://orcid.org/0000-0001-5777-5016
9von Kriegsheim AAlexander
10Dorotikova AAnnahttps://orcid.org/0009-0008-7289-8557
11Andrysik ZZdenekhttps://orcid.org/0000-0002-6723-6849
12Vichova RRachel
13Vacek OOndrejhttps://orcid.org/0000-0002-5199-8689
14Soucek KKarelhttps://orcid.org/0000-0001-7283-8150
15Uldrijan SStjepanhttps://orcid.org/0000-0001-8316-2539

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Eukaryotic Initiation Factor-4FMajor topic
GTP PhosphohydrolasesMajor topic
MAP Kinase Signaling SystemMajor topic
MelanomaMajor topic
Membrane ProteinsMajor topic
MutationMajor topic
Proto-Oncogene Proteins B-rafMajor topic
Animals
Humans
Mice
Cell Line, Tumor
Dual Specificity Phosphatase 6
Extracellular Signal-Regulated MAP Kinases
Eukaryotic Initiation Factor-4E

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
LX22NPO5102European Commission (EC)PubMed
18/SPP/3522Science Foundation Ireland (SFI)PubMed
GA22-30397SGrantová Agentura České Republiky (GAČR)PubMed
CZ.02.1.01/0.0/0.0/16_019/0000868EC | European Regional Development Fund (ERDF)PubMed
208402/Z/17Wellcome Trust (WT)PubMed
Wellcome TrustUnited KingdomPubMed
GA20-22984SGrantová Agentura České Republiky (GAČR)PubMed

Source PubMed

Download CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127533468Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.Cell Cycle2016https://conductscience.org/library/papers/27533468PubMed
29155017Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.EMBO J1997https://conductscience.org/library/papers/9155017PubMed
325079330eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.Nature2014https://conductscience.org/library/papers/25079330PubMed
428910386DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.PLoS One2017https://conductscience.org/library/papers/28910386PubMed
526603897SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.Cancer Res2015https://conductscience.org/library/papers/26603897PubMed
634857952Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.Nat Genet2021https://conductscience.org/library/papers/34857952PubMed
731723131eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma.Nat Commun2019https://conductscience.org/library/papers/31723131PubMed
825743081Targeting the translation machinery in cancer.Nat Rev Drug Discov2015https://conductscience.org/library/papers/25743081PubMed
919251651(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.Proc Natl Acad Sci U S A2009https://conductscience.org/library/papers/19251651PubMed
1030401534Dual-specificity MAP kinase phosphatases in health and disease.Biochim Biophys Acta Mol Cell Res2019https://conductscience.org/library/papers/30401534PubMed
1118300768The MAPK pathway in melanoma.Curr Opin Oncol2008https://conductscience.org/library/papers/18300768PubMed
128766822Insulin-stimulated phosphorylation of initiation factor 4E is mediated by the MAP kinase pathway.FEBS Lett1996https://conductscience.org/library/papers/8766822PubMed
1327309803Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.Nature2016https://conductscience.org/library/papers/27309803PubMed
1431844050An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.Nat Commun2019https://conductscience.org/library/papers/31844050PubMed
1520215513Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).Cancer Res2010https://conductscience.org/library/papers/20215513PubMed
1628199182One reporter for in-cell activity profiling of majority of protein kinase oncogenes.Elife2017https://conductscience.org/library/papers/28199182PubMed
1718439900AMPK phosphorylation of raptor mediates a metabolic checkpoint.Mol Cell2008https://conductscience.org/library/papers/18439900PubMed
1828923912Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.Cancer Discov2018https://conductscience.org/library/papers/28923912PubMed
1917018604In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.Cancer Res2006https://conductscience.org/library/papers/17018604PubMed
209878069Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E.EMBO J1999https://conductscience.org/library/papers/9878069PubMed

See all 49 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
42850324Mapping the functional dark proteome in cancer.Nat Rev Cancer2026https://conductscience.org/library/papers/42850324PubMed
42707299Dual MAO A and HSP90 inhibitors enhance anti-PD-1 therapy and suppress colorectal cancer.Front Pharmacol2026https://conductscience.org/library/papers/42707299PubMed
42599619Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.J Neurooncol2026https://conductscience.org/library/papers/42599619PubMed
42519028The dual specificity phosphatase 2 act as distal regulatory node in T cell signaling.iScience2026https://conductscience.org/library/papers/42519028PubMed
42050705Translational control of AMPK activity in melanoma.Cell Commun Signal2026https://conductscience.org/library/papers/42050705PubMed
41865130ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability.Cell Mol Life Sci2026https://conductscience.org/library/papers/41865130PubMed
41807883BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Mol Biomed2026https://conductscience.org/library/papers/41807883PubMed
41799498Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAFV600E Mutant A375 Melanoma Cells.Oncol Res2026https://conductscience.org/library/papers/41799498PubMed
41754923Atlas-Guided Nanocarrier Strategies Targeting Spatial NTRK2/MAPK Signaling in EGFR-TKI-Resistant Niches of Esophageal Squamous Cell Carcinoma.Pharmaceutics2026https://conductscience.org/library/papers/41754923PubMed
41648055Unveiling a BRAF Signature Proficient in Accurately Capturing Oncogenic Activity and Guiding Prognostic Prediction Across Multiple Cancers.MedComm (2020)2026https://conductscience.org/library/papers/41648055PubMed
39809544eIF4F-mediated dysregulation of mRNA translation in cancer.RNA2025https://conductscience.org/library/papers/39809544PubMed
39436655eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations.Proc Natl Acad Sci U S A2024https://conductscience.org/library/papers/39436655PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39436655

GET https://conductscience.org/api/papers/v1/39436655/references?page=2